VIS Business Summary

Visgeneer, Inc. (4197.TWO), identified by the name variant VIS, is a Taiwan-based biotechnology company that generates revenue through the development, manufacture, and global distribution of in-vitro diagnostic (IVD) systems and specialized skincare products. The company’s business model is structured around two primary segments: the Healthcare unit, which focuses on multi-parameter blood monitoring systems (measuring glucose, cholesterol, ketone, and uric acid) under the eBmonitor brand, and the Skincare unit, which utilizes its patented "Ollantein" zeaxanthin extract for anti-aging cosmetics under the CoreSence brand. Additionally, Visgeneer derives significant income from professional OEM/ODM contract manufacturing for international medical device partners. Within the competitive landscape, Visgeneer operates as a specialized niche player alongside larger Taiwanese peers such as Bionime Corporation, Taidoc Technology, and Rossmax International, distinguishing itself through its integration of bioinformatics and proprietary botanical synthesis. The company was founded in 2005 by Dr. Ken-Shwo Dai (Keng-Shuo Dai), who continues to lead the organization as the current Chairman and Chief Executive Officer. Dr. Dai holds a PhD from the University of Toronto and possesses a distinguished pedigree in bioinformatics and molecular biology, which has been the driving force behind the company’s extensive patent portfolio in cancer gene diagnostics and specialized fermentation processes. The executive leadership team also includes Chief Financial Officer Shu-Chen Li, who has managed the firm’s financial strategy and capital operations since 2020. Visgeneer’s governance is overseen by a stable board of directors featuring long-term members such as Huo-Fu Tai and Chuan-Ping Lo, and the company remains recognized as a strategic enterprise within Taiwan’s emerging high-tech industry, supported by a mix of institutional and private capital.